Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis

Catheterization and Cardiovascular Interventions

Volumn 87, Issue 6, 2016, Pages 1080-1091

  Goel, Sachin S ^a   Dilip Gajulapalli, Rama ^b   Athappan, Ganesh ^c   Philip, Femi ^d   Gupta, Supriya ^b   Murat Tuzcu, E ^b   Ellis, Stephen G ^b   Mishkel, Gregory ^a   Kapadia, Samir R ^b  

^a ST JOHN'S HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

balloon; drug coated eluting; drug eluting; stent; stent restenosis

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RISK REDUCTION; SIROLIMUS ELUTING CORONARY STENT; STENT THROMBOSIS; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; VERY ELDERLY; ADVERSE EFFECTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DISEASE MANAGEMENT; PROSTHESIS DESIGN; PROSTHESIS FAILURE;

CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DISEASE MANAGEMENT; DRUG-ELUTING STENTS; HUMANS; PROSTHESIS DESIGN; PROSTHESIS FAILURE;

EID: 84949571082     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26151     Document Type: Article

References (50)

1. Moher D, Liberati A., Reporting systematic reviews and meta-analyses: asking authors, peer reviewers, editors and funders to do better. Med Clin (Barc) 2010; 135: 505-506.
2. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al., Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
3. Abe M, Kimura T, Morimoto T, Taniguchi T, Yamanaka F, Nakao K, et al., Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 2010; 122: 42-51.
4. Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al., Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. Lancet 2013; 381: 461-467.
5. Chevalier B, Moulichon R, Teiger E, Brunel P, Metzger JP, Pansieri M, et al., One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. J Interv Cardiol 2012; 25: 586-595.
6. Ishikawa K, Aoyama Y, Hirayama H., Management of drug-eluting stent restenosis. J Invasive Cardiol 2012; 24: 178-182.
7. Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura Y, Kuroda N, et al., Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: Retrospective analysis of 4 Japanese hospitals. Circ J 2009; 73: 867-871.
8. Ko YG, Kim JS, Kim BK, Choi D, Hong MK, Jeon DW, et al., Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]). Am J Cardiol 2012; 109: 607-613.
9. Liistro F, Fineschi M, Grotti S, Angioli P, Carrera A, Ducci K, et al., Long-term clinical outcome of alternative treatment strategies for drug-eluting stents restenosis. EuroIntervention 2009; 5: 454-459.
10. Maluenda G, Ben-Dor I, Gaglia MA Jr, Wakabayashi K, Mahmoudi M, Sardi G, et al., Clinical outcomes and treatment after drug-eluting stent failure: The absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv 2012; 5: 12-19.
11. Sardella G, Colantonio R, De Luca L, Conti G, Di Roma A, Mancone M, et al., Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. J Cardiovasc Med (Hagerstown) 2009; 10: 469-473.
12. Song HG, Park DW, Kim YH, Ahn JM, Kim WJ, Lee JY, et al., Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol 2012; 59: 1093-1100.
13. Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C., Long-term clinical follow-up of drug-eluting stent restenosis treatment: Retrospective analysis from two high volume catheterisation laboratories. EuroIntervention 2010; 5: 703-708.
14. Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, et al., Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011; 4: 149-154.
15. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, et al., A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: The PEPCAD-DES study. J Am Coll Cardiol 2012; 59: 1377-1382.
16. Abdel-Wahab M, Nienaber CA, Mostafa AE, Sabin G, Tebbe U, Hochadel M, et al., Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: Results from the first phase of the prospective multicentre German DES.DE registry. EuroIntervention 2011; 7: 201-208.
17. Abizaid A, Costa JR Jr, Banning A, Bartorelli AL, Dzavik V, Ellis S, et al., The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: Insights from the e-SELECT (Multicenter Post-Market Surveillance) registry. JACC Cardiovasc Interv 2012; 5: 64-71.
18. Alfonso F, Perez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, Garcia-Touchard A, et al., Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv 2012; 5: 728-737.
19. Almalla M, Pross V, Marx N, Hoffmann R., Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. Coron Artery Dis 2012; 23: 492-496.
20. Cosgrave J, Melzi G, Corbett S, Biondi-Zoccai GG, Babic R, Airoldi F, et al., Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. Am Heart J 2007; 153: 354-359.
21. Ribamar Costa J, Sousa AG, Moreira A, Alves da Costa R, Cano, MN, Maldonado G, et al., Comparison of the very long term (>1 year) outcomes of drug-eluting stents for the treatment of bare-metal and drug-eluting stent restenosis. EuroIntervention 2009; 5: 448-453.
22. Dhakam S, Jafferani A, Ahmed H, Rahman N, Gowani A., Safety and efficacy of drug-eluting balloons in the treatment of drug-eluting in-stent restenosis: Experience of a tertiary care hospital. J Invasive Cardiol 2012; 24: 335-338.
23. Faramarzi N, Salarifar M, Kassaian SE, Zeinali AM, Alidoosti M, Pourhoseini H, et al., Mid-term follow-up of drug-eluting stenting for in-stent restenosis: Bare-metal stents versus drug-eluting stents. J Tehran Heart Cent 2013; 8: 14-20.
24. Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Steinberg DH, et al., Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 2007; 70: 9-14.
25. Ge H, Zhang Q, Zhou W, He Q, Han ZH, He B., Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent. J Zhejiang Univ Sci B 2010; 11: 553-560.
26. Hehrlein C, Dietz U, Kubica J, Jorgensen E, Hoffmann, E, Naber C, et al., Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. Cardiovasc Revasc Med 2012; 13: 260-264.
27. Jensen JK, Jensen LO, Terkelsen CJ, Lassen JF, Tilsted HH, Hansen KN, et al., Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: From Western Denmark Heart Registry. Catheter Cardiovasc Interv 2013; 81: 260-265.
28. Whan Lee C, Kim SH, Suh J, Park DW, Lee SH, Kim YH, et al., Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheter Cardiovasc Interv 2008; 71: 594-598.
29. Lee SS, Price MJ, Wong GB, Valencia R, Damani S, Sawhney N, et al., Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. Am J Cardiol 2006; 98: 1345-1348.
30. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, et al., Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010; 55: 2710-2716.
31. Meliga E, Benedictis De, Gagnor M, Scrocca A, Lombardi I, Aranzulla PT, et al., New drug-eluting stent implantation for recalcitrant in-stent restenosis treated with drug-eluting stents. The Stent-in-Stent Cube (SIS(3)) registry. J Invasive Cardiol 2011; 23: 365-368.
32. Nakamura S, Bae J-H, Cahyadi YH, Udayachalerm W, Tresukosol D, Tansuphaswadikul S,. Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent on the Outcome of Patients with Sirolimus-Eluting Stent Failure. Multicenter registry in Asia. Washington, D.C.: Transcatheter Cardiovascular Therapeutics; 2007.
33. Nishihira K, Shibata Y, Ishikawa T, Nomura K, Nakama T, Mine D, et al., Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis. Circ J 2010; 74: 2329-2333.
34. Park SJ, Kim KH, Oh IY, Shin DH, Park, KI, Seo MK, et al., Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ J 2010; 74: 1837-1845.
35. Steinberg DH, Gaglia MA Jr, Pinto Slottow TL, Roy P, Bonello L, De Labriolle A, et al., Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. Am J Cardiol 2009; 103: 491-495.
36. Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, et al., The Valentines Trial: Results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention 2011; 7: 705-710.
37. Torguson R, Sabate M, Deible R, Smith K, Chu WW, Kent KM, et al., Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol 2006; 98: 1340-1344.
38. Vaquerizo B, Serra A, Miranda-Guardiola F, Martinez V, Antoni Gomez-Hospital J, Iniguez A, et al., One-year outcomes with angiographic follow-up of paclitaxel-eluting balloon for the treatment of in-stent restenosis: Insights from Spanish multicenter registry. J Interv Cardiol 2011; 24: 518-528.
39. Yamashita K, Ochiai M, Yakushiji T, Ebara S, Okabe T, Yamamoto MH, et al., Repeat drug-eluting stent implantation for in-stent restenosis: First- or second-generation stent. J Invasive Cardiol 2012; 24: 574-578.
40. Yan RQ, Chen JL, Gao LJ, Yang YJ, Li JJ, Qiao SB, et al., Sirolimus-eluting stents for treatment of drug-eluting versus bare-metal stents restenosis: 42-month clinical outcomes from a Chinese single center. Chin Med J (Engl) 2012; 125: 3398-3403.
41. Bucher HC, Guyatt GH, Griffith LE, Walter SD., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
42. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R., In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897-907.
43. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al., 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-e122.
44. Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, et al., Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: A network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv 2015; 8: 382-394.
45. Alfonso F, Garcia J, Perez-Vizcayno MJ, Hernando L, Hernandez R, Escaned J, et al., New stent implantation for recurrences after stenting for in-stent restenosis: Implications of a third metal layer in human coronary arteries. J Am Coll Cardiol 2009; 54: 1036-1038.
46. Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, et al., Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv 2012; 5: 323-330.
47. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al., Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
48. Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, et al., Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: A report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2012; 33: 606-613.
49. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al., Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
50. Cosgrave J, Melzi G, Biondi-Zoccai GG, Airoldi F, Chieffo A, Sangiorgi GM, et al., Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006; 47: 2399-2404.